Company Overview - Nexalin Technology, Inc. designs and develops innovative neurostimulation products aimed at addressing the global mental health epidemic, utilizing bioelectronic medical technology to treat mental health issues [4]. Public Offering Details - The company announced a public offering of 3,000,000 shares of common stock at a public offering price of 5,250,000 before deducting fees and expenses [3][6]. Product Information - Nexalin's neurostimulation devices are designed to be non-invasive and undetectable, targeting deep structures in the mid-brain associated with mental health disorders. The next-generation devices are believed to enhance patient response without adverse side effects [4]. Regulatory and Compliance - The offering is conducted under a registration statement on Form S-1, which was declared effective by the SEC on June 27, 2024, and the final prospectus will be filed with the SEC [8].
Nexalin Technology Announces Pricing of $5.2 Million Public Offering